Beam Therapeutics Inc. Segments Disclosure
16. Segment Data
The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed by the chief operating decision maker, or CODM, to analyze financial performance, make decisions, and allocate resources. The Company’s . The Company manages its operations as a operating and reportable segment and the measure of segment profit or loss is consolidated net income (loss). The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources.
The internal reporting of significant segment expenses is based on the functional classification. External expenses include costs from external manufacturing, clinical and research organizations, supply chain and logistics costs, consultants, and other vendors. Employee related expenses include, employee salaries and benefits costs, employee meal, travel and entertainment spend, along with payroll related taxes and other similar items. These functional costs exclude stock-based compensation, facility and information technology costs, depreciation and amortization, and other segment items.
The table below provides information about the Company’s segment, including significant expenses, other segment items, certain other segment expenses, and a reconciliation to net income (loss):
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
License and collaboration revenue |
|
$ |
139,743 |
|
|
$ |
63,518 |
|
|
$ |
377,709 |
|
Research and development expenses |
|
|
|
|
|
|
|
|
|
|||
External research and development expenses* |
|
|
142,695 |
|
|
|
115,189 |
|
|
|
155,063 |
|
Employee related expenses* |
|
|
117,366 |
|
|
|
98,796 |
|
|
|
109,878 |
|
General and administrative expenses |
|
|
|
|
|
|
|
|
|
|||
External general and administrative expenses* |
|
|
28,319 |
|
|
|
25,115 |
|
|
|
40,016 |
|
Employee related expenses* |
|
|
43,124 |
|
|
|
34,822 |
|
|
|
31,305 |
|
Facility and information technology related expenses* |
|
|
59,093 |
|
|
|
55,911 |
|
|
|
53,804 |
|
Depreciation and amortization |
|
|
22,294 |
|
|
|
21,925 |
|
|
|
20,012 |
|
Stock-based compensation |
|
|
94,244 |
|
|
|
120,662 |
|
|
|
98,647 |
|
Interest and other income |
|
|
(43,733 |
) |
|
|
(49,094 |
) |
|
|
(46,676 |
) |
Income tax expense |
|
|
— |
|
|
|
39 |
|
|
|
1,366 |
|
Other segment items |
|
|
(243,667 |
) |
|
|
16,895 |
|
|
|
46,821 |
|
Net income (loss) |
|
$ |
(79,992 |
) |
|
$ |
(376,742 |
) |
|
$ |
(132,527 |
) |
* Denotes significant segment expense
Other Segment Items includes:
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.